Search the Newsreel

MiMedx Group Inc (MDXG) Stock News Today

This article from TradingKey provides current stock information for MiMedx Group Inc (MDXG), including its stock price, market cap, and P/E ratio. It notes that more news regarding MDXG's earnings, analyst ratings, and key developments will be available soon. The page serves as a …

MiMedx (MDXG) Q2 2026 Earnings Call Transcript

MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear

MiMedx Group's recent earnings might seem weak, but a deeper analysis reveals a stronger financial position than initially perceived. The company's accrual ratio of -0.36 indicates that its free cash flow significantly exceeded its reported statutory profit, suggesting an understatement of its true earnings …

MiMedx Group Inc (MDXG) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for MiMedx Group Inc (MDXG), highlighting its current earnings forecast score of 8.00 and an average analyst price target of $12.00. Based on 5 analysts, the stock has a "Buy" rating with a potential upside of 61.29%. Key …

MiMedx Group Number of Employees 2026 | Employee Count & Headcount Data

MiMedx Group (NASDAQ: MDXG) had 799 employees globally as of March 2026, representing a 1.0% decline since 2023. The company is actively hiring, with 40 active job postings in 2026, though new postings are slowing. The workforce is primarily concentrated in the United States, …

Renaissance Technologies LLC Has $11.93 Million Stake in MiMedx Group, Inc $MDXG

Renaissance Technologies LLC increased its stake in MiMedx Group, Inc (MDXG) by 22.4% in the first quarter, now holding 3.02 million shares valued at $11.93 million, representing 2.03% of the company. Despite some recent analyst price target reductions and downgrades, the stock maintains a …

Sanara MedTech (SMTI) plans business combination with MiMedx Group to build regenerative leader

Sanara MedTech (SMTI) has announced a proposed business combination with MiMedx Group, Inc., aiming to establish a leading regenerative medicine company focused on surgical and wound care applications. The transaction is expected to close by year-end, pending regulatory and shareholder approvals. Until then, both …

MiMedx Group Q2 Earnings Call Highlights

MiMedx Group announced its Q2 results and the acquisition of Sanara MedTech for $35 per share, expecting the deal to close by the end of 2026. This acquisition will significantly shift MiMedx's revenue mix towards surgical products, expanding its market opportunity by an estimated …

ETFs Investing in MiMedx Group, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold shares of MiMedx Group, Inc. (MDXG). It provides a detailed table with each ETF's market value of MDXG holdings, weight in the ETF, issuer, management style, focus, expense ratio, assets under management (AUM), price, …

MiMedx Group (SMTI) details Sanara MedTech buyout and 2027 profit goals

MiMedx Group announced its plan to acquire Sanara MedTech for $35 per share, aiming to combine Sanara's surgical revenue with MiMedx's soft-tissue surgical franchise and achieve at least $20 million in annual cost synergies. Despite a 35% year-over-year net sales drop in Q2 2026 …

MiMedx Group (NASDAQ:MDXG) Shares Gap Down on Disappointing Earnings

MiMedx: Q2 Earnings Snapshot

This article provides a brief snapshot of MiMedx's Q2 earnings. No specific financial details or further information about the earnings are included in the provided content.

MiMedx Group to Acquire Sanara MedTech in Merger

MiMedx Group announced its agreement to acquire Sanara MedTech in a cash-and-stock merger, valuing Sanara at $35 per share, representing approximately $350 million in enterprise value and a 46% premium. This acquisition aims to nearly double MiMedx's surgical revenue, enhance profitability, and generate over …

Transcript : MiMedx Group, Inc., Q2 2026 Earnings Call, Jul 29, 2026

This article is a transcript of MiMedx Group, Inc.'s Q2 2026 Earnings Call, which took place on July 29, 2026. The content is primarily a message from the operator indicating the start of the conference call. The full transcript is reserved for subscribers.

Is MiMedx Group Inc (MDXG) Undervalued After Q2 Earnings Beat? E

MiMedx Group (Nasdaq: MDXG) posts Q2 loss, plans $350M Sanara acquisition

MiMedx Group reported sharply weaker Q2 2026 results with a net loss of $14.84 million, a significant drop from a prior-year profit, primarily due to a 61.1% decline in Wound revenue following Medicare reimbursement changes. Despite a 15.1% increase in Surgical revenue, overall net …

MIMEDX Announces Second Quarter 2026 Operating & Financial Results

MIMEDX (Nasdaq: MDXG) announced its second quarter 2026 operating and financial results, reporting net sales of $64 million, a 35% decrease year-over-year, largely due to Medicare reimbursement changes impacting its Wound business. Despite a strong 15% growth in its Surgical franchise, the company posted …

MIMEDX GROUP, INC. Q2 2026: Revenue $64.36M, EPS ($0.1) — 10-Q Summary

MIMEDX GROUP, INC. (MDXG) reported second-quarter 2026 results, showing a significant decline in revenue and a net loss, primarily due to Medicare reimbursement changes and reduced wound-product sales. Revenue fell to $64.36M from $98.61M year-over-year, leading to a diluted EPS of ($0.1). The company …

MiMedx Group (NASDAQ:MDXG) Releases Earnings Results, Meets Expectations

MiMedx earnings missed by $0.03, revenue topped estimates

MiMedx to buy Sanara MedTech (Nasdaq: SMTI) in $350 million cash-stock deal

Earnings To Watch: MiMedx Group Inc (MDXG) Q2 2026 -- GF Value Sees 35% Upside

MiMedx Group Inc (MDXG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of MiMedx Group Inc's (MDXG) stock performance, market capitalization, and P/E ratio. It specifically notes that the company has not distributed any dividends over the past five years. The page indicates financial and corporate information for MDXG available on …

MiMedx Group Inc (MDXG) Cash Flow

This article provides a detailed cash flow statement for MiMedx Group Inc (MDXG), covering quarterly and annual data up to FY2026Q1. It breaks down various cash flow components including operating, investing, and financing activities, along with changes in working capital and specific asset transactions. …

MiMedx Group, Inc Revenue Breakdown – BOATS:MDXG

MiMedx Group, Inc. (MDXG) last year generated $418.63 million in revenue, with its top-performing segment, Wound, contributing $276.33 million. The United States was the primary geographic contributor, accounting for the entire $418.63 million in revenue last year, showing an increase from $348.88 million the …

MiMedx Group Inc (MDXG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MiMedx Group Inc (MDXG), noting its current valuation score of 6.65 and its position within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, comparing it to historical highs and lows, while also …

MiMedx Group Inc (MDXG) Financial Health: Profitability & Balance Sheet Analysis

MiMedx Group Inc (MDXG) has a robust financial status with a score of 8.21, ranking highly in the Biotechnology & Medical Research industry. Despite this, its latest quarterly revenue decreased by 33.12% year-over-year, and net profit saw a 254.63% decrease. The report highlights undisclosed …

MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070

MiMedx Group Inc. (MDXG) shows strong fundamentals and high growth potential, with its valuation assessed as fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts have given it a "Buy" rating with a target price of 6.60. …

MiMedx Group, Inc (MDXG) Investor Outlook: Exploring a 52.42% Potential Upside Amidst Biotech Innovations

MiMedx Group, Inc. (MDXG) offers a potential 52.42% upside for investors, driven by its specialization in placental tissue allografts and innovative healthcare solutions. Despite a reported revenue growth rate of -33.10%, the company boasts a strong return on equity and free cash flow. Analysts …

MIMEDX will review second-quarter results in a July 29 webcast

MiMedx (Nasdaq: MDXG) announced it will release its second-quarter 2026 operating and financial results after market close on Wednesday, July 29, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. …

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its Q2 2026 operating and financial results after market close on July 29, 2026. The company's senior management will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to …

MDXG Forecast — Price Target — Prediction for 2027

MDXG Q1 2026 Earnings: EPS Miss Widens Losses, Stock Slips on Surprise - New Analyst Coverage